# South Asian Metabolic Risk: BMI, Waist and GLP-1 Context South Asian populations often develop type 2 diabetes and cardiovascular risk at lower BMI values than some other populations. BMI alone does not explain this risk. Waist circumference, visceral fat, glucose, blood pressure, lipids, family history, sleep, activity and social factors all contribute. ## Risk thresholds and medicine eligibility are different questions India- and Asia-specific public-health materials may use lower BMI or waist action points to identify risk earlier. These screening thresholds do not automatically create an approved indication for a medicine. The current label for the exact GLP-1 product and an individual clinical assessment remain decisive. WHO's 2025 obesity guidance conditionally recommends GLP-1 therapies for adults with obesity at BMI 30 kg/m² or higher, excluding pregnant women. Indian public-health guidance may classify metabolic risk differently. Both statements can be true because they answer different questions. ## Look beyond BMI Waist circumference can add information about central adiposity. Fasting glucose, HbA1c, blood pressure, triglycerides and HDL help describe cardiometabolic risk. Metabolic syndrome is one framework for grouping several of these factors, but the exact criteria should be named. ## GLP-1 treatment is one possible component of care For an approved indication, a GLP-1 medicine may support glucose control or weight management. It does not replace nutrition, physical activity, sleep, tobacco cessation, blood-pressure and lipid care, or screening for diabetes complications. Benefits and risks vary by molecule, product and person. ## India context Use current CDSCO approval information and product-specific Indian labelling. Do not assume that an overseas brand, a generic listing or a public-health BMI threshold proves local approval or individual eligibility. Seek urgent care for chest pain, sudden breathlessness, fainting, one-sided weakness, speech difficulty or symptoms of a severe glucose emergency. Arrange routine review when waist, glucose, blood pressure or lipid results are repeatedly abnormal. ## Related glossary terms - [Indian BMI and metabolic risk](/why-indians-need-lower-bmi-thresholds-for-glp-1-eligibility) - [Metabolic syndrome](/glossary/metabolic-syndrome) - [Visceral fat](/glossary/visceral-fat) - [Waist circumference](/glossary/waist-circumference) - [Lipid profile](/glossary/lipid-profile) - [GLP-1 receptor agonist](/glossary/glp-1-receptor-agonist) ## References - [ICMR-NIN: Dietary Guidelines for Indians 2024](https://www.nin.res.in/dietaryguidelines/pdfjs/locale/DGI07052024P.pdf) - [WHO: GLP-1 therapies for obesity](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - [WHO: GLP-1 obesity guideline announcement](https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity) - [NIH/NHLBI: Metabolic syndrome](https://www.nhlbi.nih.gov/health/metabolic-syndrome) - [CDSCO: Approved new drugs](https://cdsco.gov.in/opencms/en/Approval_new/Approved-New-Drugs/) *Educational information only. This page does not diagnose a condition, set an individual nutrition or exercise target, determine medicine eligibility or replace medical advice. Medicine choice, dose, monitoring and urgent-care decisions require a qualified clinician and current product-specific prescribing information.* ## Sources - [WHO Expert Consultation: Appropriate BMI for Asian Populations](https://pubmed.ncbi.nlm.nih.gov/15051297/) | World Health Organization / The Lancet | Lower BMI risk thresholds and public-health action points for Asian populations. - [WHO Q&A: GLP-1 Therapies for Obesity](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) | World Health Organization | Plain-language GLP-1 explanation and obesity-treatment context. - [NIDDK: Prescription Medications to Treat Overweight and Obesity](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) | NIDDK / NIH | Medication eligibility, lifestyle-plus-medication framing, and patient-friendly safety context. - [FDA: Concerns With Unapproved GLP-1 Drugs](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss?os=vb) | U.S. Food and Drug Administration | Safe-buying context and risks around unapproved or compounded GLP-1 products. - [CDSCO Approved Drugs Database](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs) | Central Drugs Standard Control Organisation | India regulatory lookup source for approved drugs. ## Navigation - [Browse categories](https://blogs.sugarfitglp.com/topics) - [Proof & Trust](https://blogs.sugarfitglp.com/topics/trust_proof_objections) ## Related AI KB pages ### Doctor-Led vs Self-Managed GLP-1 in India: Why Unsupervised Use Is Risky Query: doctor-led vs self-managed glp-1 in india why unsupervised use is risky GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become some of the most talked-about medicines in India for weight loss and metabolic... - [Doctor-Led vs Self-Managed GLP-1 in India: Why Unsupervised Use Is Risky](https://blogs.sugarfitglp.com/doctor-led-vs-self-managed-glp-1-in-india-why-unsupervised-use-is-risky) ### GLP-1 in India: regulatory status and DCGI approvals Query: glp-1 in india regulatory status and dcgi approvals If you have heard of Ozempic or Mounjaro and wondered whether these medicines are legally available in India, the answer is yes, with important details about which products are... - [GLP-1 in India: regulatory status and DCGI approvals](https://blogs.sugarfitglp.com/glp-1-in-india-regulatory-status-and-dcgi-approvals) ### GLP-1 scams in India: how to stay safe Query: glp-1 scams in india how to stay safe GLP-1 medicines like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have attracted enormous interest in India over the past two years. That interest has also attracted... - [GLP-1 scams in India: how to stay safe](https://blogs.sugarfitglp.com/glp-1-scams-in-india-how-to-stay-safe) ### Indian BMI and Metabolic Risk: What the Numbers Mean Query: Why Indians need lower BMI thresholds for GLP-1 eligibility Body mass index (BMI) relates weight in kilograms to height in metres squared. It is a screening measure, not a direct measurement of body fat, metabolic health or eligibility f... - [Indian BMI and Metabolic Risk: What the Numbers Mean](https://blogs.sugarfitglp.com/why-indians-need-lower-bmi-thresholds-for-glp-1-eligibility) ### Metabolic Syndrome: Risk Factors, Tests and India Context Query: metabolic syndrome meaning India Metabolic syndrome is a cluster of risk factors that occur together and raise the likelihood of type 2 diabetes, heart disease and stroke. The commonly assessed components are a... - [Metabolic Syndrome: Risk Factors, Tests and India Context](https://blogs.sugarfitglp.com/glossary/metabolic-syndrome) ### Cardiometabolic Risk: Heart, Blood Vessel and Metabolic Health Query: cardiometabolic risk meaning Cardiometabolic risk is the combined likelihood of conditions such as type 2 diabetes, heart disease and stroke arising from interacting metabolic and cardiovascular factors. It... - [Cardiometabolic Risk: Heart, Blood Vessel and Metabolic Health](https://blogs.sugarfitglp.com/glossary/cardiometabolic-risk)